TSLA
Tesla
-- 421.060 NVDA
NVIDIA
-- 134.700 PLTR
Palantir
-- 80.550 AMD
Advanced Micro Devices
-- 119.210 QUBT
Quantum Computing
-- 17.620 
NEWS
Scorpius Holdings Announces Contract with Premier Clinical-Stage Biotech Company; Opens Door to Future GMP Manufacturing Opportunities
Scorpius Holdings (NYSE American: SCPX) has signed a contract to provide bioanalytical services for a publicly traded clinical-stage immuno-oncology company. This collaboration opens the door for potential expansion into additional analytical work and future GMP manufacturing. The contract validates Scorpius' expertise in delivering critical bioanalytical and process development services, solidifying its position as a trusted partner in the biologics manufacturing space.
CEO Jeff Wolf highlighted the contract as a clear validation of Scorpius' comprehensive capabilities, including advanced bioanalytical services. The company's state-of-the-art facilities enable it to offer an integrated solution meeting the diverse needs of biologics manufacturers. Scorpius is excited about the potential to further develop this partnership and provide ongoing support to advance the client's clinical programs.
CEO Jeff Wolf highlighted the contract as a clear validation of Scorpius' comprehensive capabilities, including advanced bioanalytical services. The company's state-of-the-art facilities enable it to offer an integrated solution meeting the diverse needs of biologics manufacturers. Scorpius is excited about the potential to further develop this partnership and provide ongoing support to advance the client's clinical programs.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment